- Today's Hot Chat Topics
- Member Benefits
- Manage your personalised Watchlist.
- Set up an online Virtual Portfolio.
- Participate in Share Chat.
- See more trades and director dealings.
- Play the Fantasy Share Trading Game.
Share:
HomeShare PricesStock PickerFinancial DiaryUK IndicesUK Industry SectorsCompany LookupShare RisersShare FallersBroker RatingsFinance GlossarySMS ServicesShare ChatFinance NewsBlogsLive PricesShares BookshopFinance ToolsMembers
Latest Share Chat
1spatial Holdings Share News (SPA)
Share News for 1spatial Holdings (SPA)
| Share Price: 8.375 | Bid: 8.00 | Ask: 8.25 | Change: 0.25 (+3.08%) |  | ||||||
| ||||||||||
SR Pharma says clinical trials for Atu027 treatment to begin in 2007
Wed, 29th Nov 2006 08:07
LONDON (AFX) - SR Pharma PLC said phase I of the clinical trial on using its RNA-interference
In a research update, the AIM-listed biopharmaceutical company said its product was more effective in the prevention of metastases than Gemcitabine, an approved drug for palliative treatment.
The company said studies showed the therapeutic efficacy of its product in pre-clinical models of pancreatic cancer when compared to the standard care treatment and said data showed cancer growth was inhibited and prevented metastatic spread, with no adverse events.
newsdesk@afxnews.com
ssr/slm
COPYRIGHT
Copyright AFX News Limited 2006. All rights reserved.
The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
LONDON (AFX) - SR Pharma PLC said phase I of the clinical trial on using its RNA-interference
product candidate Atu027 RNAi in patients suffering from pancreatic cancer is scheduled to start in 2007.
In a research update, the AIM-listed biopharmaceutical company said its product was more effective in the prevention of metastases than Gemcitabine, an approved drug for palliative treatment.
The company said studies showed the therapeutic efficacy of its product in pre-clinical models of pancreatic cancer when compared to the standard care treatment and said data showed cancer growth was inhibited and prevented metastatic spread, with no adverse events.
newsdesk@afxnews.com
ssr/slm
COPYRIGHT
Copyright AFX News Limited 2006. All rights reserved.
The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
SR Pharma plans more pre-clinical Atu027 tests, gets AtuRNAi milestone payment
LONDON (Thomson Financial) - SR Pharma PLC said it intends to carry out more pre-clinical testing on its lead molecule Atu027, its first RNAi ca[26 Apr '07]
SR Pharma chairman Iain Ross buys 100,000 shares in co at 75.75p each
LONDON (AFX) - SR Pharma PLC said chairman Iain Ross yesterday bought 100,000 shares at 75.75 pence each, giving him a 0.09 pct stake in the com[3 Apr '07]
SR Pharma annual losses widen
LONDON (AFX) - SR Pharma PLC, which specialises in RNAi-based therapeutics, reported widening annual losses on higher research and development c[30 Mar '07]
UK smallcap opening - Advent Air ticks up on interim profits surge
LONDON (AFX) - Advent Air ticked up 1/2 to 13-1/4 pence after the company revealed a 245 pct leap in first-half pretax profits on the back of gr[16 Mar '07]
SR Pharma says FDA approves investigational application for second siRNA product
LONDON (AFX) - SR Pharma PLC said the US Food and Drug Administration has approved an Investigational New Drug application for a second small in[16 Mar '07]
SR Pharma to get 1.5 mln usd milestone payment as blindness drug trial starts
LONDON (AFX) - Biopharmaceutical company SR Pharma PLC said it will get a 1.5 mln usd milestone payment to mark the start of a clinical trial on[5 Feb '07]
SR Pharma to conduct full toxicological evaluation of RNAi candidate Atu027
LONDON (AFX) - Biopharmaceutical company SR Pharma PLC said it will proceed with a full, 28-day toxicological evaluation of its RNAi product can[30 Jan '07]
RPT SR Pharma granted core RNAi patent by European Patent Office
(repeating to remove text from bottom of story) LONDON (AFX) - SR Pharma plc said the European Patent Office has granted the company its cor[3 Jan '07]
